Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoyu Jiangzhi Capsules (marketed under the brand name Ketailong) is a Traditional Chinese Medicine (TCM) developed and manufactured by Guiyang Xintian Pharmaceutical. It is specifically indicated for the treatment of hyperlipidemia, particularly in patients diagnosed with the TCM syndrome of blood stasis and phlegm obstruction. The formulation is composed of several herbal ingredients, including Hawthorn (山楂), Lotus Leaf (荷叶), Alisma (泽泻), Turmeric (姜黄), Gynostemma (绞股蓝), and Cassia Seed (决明子). These components work synergistically to promote blood circulation, remove blood stasis, and resolve phlegm to lower blood lipid levels. The drug is administered orally in capsule form and has been approved for marketing in China (NMPA approval number 国药准字Z20025073).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoyu Jiangzhi Capsules.